JP2021534131A5 - - Google Patents

Info

Publication number
JP2021534131A5
JP2021534131A5 JP2021506986A JP2021506986A JP2021534131A5 JP 2021534131 A5 JP2021534131 A5 JP 2021534131A5 JP 2021506986 A JP2021506986 A JP 2021506986A JP 2021506986 A JP2021506986 A JP 2021506986A JP 2021534131 A5 JP2021534131 A5 JP 2021534131A5
Authority
JP
Japan
Prior art keywords
seq
peptide
cationic
hyp
peptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021506986A
Other languages
English (en)
Japanese (ja)
Other versions
JP7663492B2 (ja
JP2021534131A (ja
Filing date
Publication date
Priority claimed from GBGB1812972.6A external-priority patent/GB201812972D0/en
Application filed filed Critical
Publication of JP2021534131A publication Critical patent/JP2021534131A/ja
Publication of JP2021534131A5 publication Critical patent/JP2021534131A5/ja
Priority to JP2025062268A priority Critical patent/JP2025106403A/ja
Application granted granted Critical
Publication of JP7663492B2 publication Critical patent/JP7663492B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506986A 2018-08-09 2019-08-09 細胞透過性ペプチド Active JP7663492B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025062268A JP2025106403A (ja) 2018-08-09 2025-04-04 細胞透過性ペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1812972.6A GB201812972D0 (en) 2018-08-09 2018-08-09 Cell-penetrating peptides
GB1812972.6 2018-08-09
PCT/GB2019/052247 WO2020030927A1 (en) 2018-08-09 2019-08-09 Cell-penetrating peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025062268A Division JP2025106403A (ja) 2018-08-09 2025-04-04 細胞透過性ペプチド

Publications (3)

Publication Number Publication Date
JP2021534131A JP2021534131A (ja) 2021-12-09
JP2021534131A5 true JP2021534131A5 (cg-RX-API-DMAC7.html) 2022-08-16
JP7663492B2 JP7663492B2 (ja) 2025-04-16

Family

ID=63667311

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506986A Active JP7663492B2 (ja) 2018-08-09 2019-08-09 細胞透過性ペプチド
JP2025062268A Pending JP2025106403A (ja) 2018-08-09 2025-04-04 細胞透過性ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025062268A Pending JP2025106403A (ja) 2018-08-09 2025-04-04 細胞透過性ペプチド

Country Status (12)

Country Link
US (2) US12268749B2 (cg-RX-API-DMAC7.html)
EP (1) EP3833376A1 (cg-RX-API-DMAC7.html)
JP (2) JP7663492B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210090157A (cg-RX-API-DMAC7.html)
CN (1) CN113347989A (cg-RX-API-DMAC7.html)
AU (2) AU2019317789B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002447A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108876A1 (cg-RX-API-DMAC7.html)
GB (1) GB201812972D0 (cg-RX-API-DMAC7.html)
IL (2) IL280678B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021001545A (cg-RX-API-DMAC7.html)
WO (1) WO2020030927A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018150196A1 (en) 2017-02-17 2018-08-23 Oxford University Innovation Limited Cell penetrating peptides modified by glycosylation
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
AU2019394177A1 (en) 2018-12-07 2021-06-10 Oxford University Innovation Limited Linkers
CA3211038A1 (en) * 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
US20240200062A1 (en) * 2021-03-12 2024-06-20 Pepgen Inc. Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates
AU2022298774A1 (en) * 2021-06-23 2023-12-14 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
WO2025264554A1 (en) 2024-06-17 2025-12-26 Pepgen Inc. Antisense oligonucleotide conjugates targeting peripheral myelin protein 22 (pmp22) and methods of use thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518521A (ja) 1998-06-20 2002-06-25 ワシントン・ユニバーシティ 医用画像解析、診断および治療のための膜透過性ペプチド錯体
IL127773A0 (en) 1998-12-28 1999-10-28 Yeda Res & Dev Saccharide conjugates and pharmaceutical compositions comprising them
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US9740817B1 (en) 2002-10-18 2017-08-22 Dennis Sunga Fernandez Apparatus for biological sensing and alerting of pharmaco-genomic mutation
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
AU2004235396B2 (en) 2003-04-29 2010-11-25 Sarepta Therapeutics, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
CA2543722C (en) 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
ES2627917T3 (es) 2004-06-28 2017-08-01 The University Of Western Australia Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
IE20060565A1 (en) 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
WO2008109105A2 (en) 2007-03-06 2008-09-12 Flagship Ventures Methods and compositions for improved therapeutic effects with sirna
US20080306001A1 (en) 2007-04-04 2008-12-11 Anzelika Liik Transcriptional modulation of extracellular matrix (ecm) of dermal fibroblasts
CA2691673A1 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2249851B1 (en) 2008-02-13 2015-04-01 Kao Corporation Method for producing hippocastanaceae plant seed extract
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
WO2009147368A1 (en) * 2008-06-04 2009-12-10 Medical Research Council Peptides
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
EP3133160B1 (en) 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
SI2607484T1 (sl) 2008-10-27 2016-11-30 Biomarin Technologies B.V. Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
HUE040445T2 (hu) 2009-11-12 2019-03-28 Univ Western Australia Antiszensz molekulák és eljárások betegségek kezelésére
NZ704191A (en) 2010-06-14 2016-05-27 Hoffmann La Roche Cell-penetrating peptides and uses therof
EP2394665A1 (en) * 2010-06-14 2011-12-14 F. Hoffmann-La Roche AG Cell-penetrating peptides and uses therof
ES2756326T3 (es) 2010-07-19 2020-04-27 Ionis Pharmaceuticals Inc Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
JP6069212B2 (ja) 2010-12-02 2017-02-01 ビオノール イミュノ エーエスBionor Immuno As ペプチド骨格設計
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
AU2011367230B2 (en) 2011-05-05 2017-08-10 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2013030569A2 (en) * 2011-08-30 2013-03-07 Michael John Gait Peptides
HK1200484A1 (zh) 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
BR112014027239A2 (pt) 2012-06-26 2017-07-18 Hoffmann La Roche peptídeo, método de identificação de peptídeos, método para o tratamento de câncer, nucleotídeo, vetor, uso de um peptídeo e invenção
AU2013316679B2 (en) 2012-09-13 2017-12-14 Les Hopitaux Universitaires De Geneve Cell penetrating peptides
US20150247141A1 (en) 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
US10111962B2 (en) 2012-09-25 2018-10-30 Genzyme Corporation Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
EP3760720A1 (en) 2013-03-14 2021-01-06 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
GB201314411D0 (en) * 2013-08-12 2013-09-25 Medical Res Council Peptide conjugates
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
US10358643B2 (en) 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
WO2015161255A1 (en) 2014-04-18 2015-10-22 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
GB201421379D0 (en) 2014-12-02 2015-01-14 Isis Innovation Ltd And Medical Res Council Molecule
EP3034074A1 (en) 2014-12-18 2016-06-22 Universitat De València, Estudi General Compound for treatment of myotonic dystrophy type 1
US10017542B2 (en) 2015-03-23 2018-07-10 Riptide Bioscience, Inc. Antimicrobial peptides and methods of use thereof
JP6817288B2 (ja) 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
US10858410B2 (en) 2015-08-12 2020-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier
JP2018530560A (ja) 2015-10-09 2018-10-18 サレプタ セラピューティクス, インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
DK3463308T4 (da) 2016-06-01 2026-02-09 Servier Ip Uk Ltd Formuleringer af polyalkylenoxid-asparaginase og fremgangsmåder til fremstilling og anvendelse deraf
CN110392583B (zh) 2016-09-15 2023-01-03 加利福尼亚大学董事会 改进的杂化的末端树枝状聚合物
WO2018150196A1 (en) 2017-02-17 2018-08-23 Oxford University Innovation Limited Cell penetrating peptides modified by glycosylation
JP2020536058A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーを処置するための併用療法
JP2020536060A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーを処置するための併用療法
EP3687519A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
AU2019394177A1 (en) 2018-12-07 2021-06-10 Oxford University Innovation Limited Linkers
WO2020214763A1 (en) 2019-04-18 2020-10-22 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
EP3987029A1 (en) 2019-06-19 2022-04-27 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
EP3997228A4 (en) 2019-07-09 2024-05-15 The Governors of the University of Alberta SKIP OF EXONS 45 TO 55 USING MUTATION-ADAPTED COCKTAILS, OF ANTISENS MORPHOLINOS, IN THE DMD GENE
GB201911403D0 (en) 2019-08-09 2019-09-25 Univ Oxford Innovation Ltd Conjugate and uses thereof
CA3211038A1 (en) 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
US20240189434A1 (en) 2021-03-12 2024-06-13 Pepgen Inc. Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates
US20240200062A1 (en) 2021-03-12 2024-06-20 Pepgen Inc. Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates

Similar Documents

Publication Publication Date Title
CN103998458B (zh) 具有中央疏水域的细胞穿透肽
JP7846169B2 (ja) 細胞透過性ペプチド
US12583889B2 (en) Cell penetrating peptides
JP2024506099A5 (cg-RX-API-DMAC7.html)
RU2009106710A (ru) Слитый пептид, предназначенный для ингибирования взаимодействия нейронного nmda-рецептора (nmdar) с белками, взаимодействующими с nmdar
JP2022543320A5 (cg-RX-API-DMAC7.html)
JP2023528207A5 (cg-RX-API-DMAC7.html)
EP2997148B1 (en) Bacteriophage
WO2003091429A1 (en) Antimicrobial polypeptide and utizliation thereof
JP2020525462A (ja) 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物
JP2023545707A5 (cg-RX-API-DMAC7.html)
JP2007535910A5 (cg-RX-API-DMAC7.html)
JP2019512004A5 (cg-RX-API-DMAC7.html)
Olmez et al. Protein-peptide interactions revolutionize drug development
Zahariev et al. Efficient synthesis and comparative studies of the arginine and Nω, Nω‐dimethylarginine forms of the human nucleolin glycine/arginine rich domain
US11865181B2 (en) Peptidic materials that traffic efficiently to the cell cytosol and nucleus
US20150329609A1 (en) Chimeric dystrophin proteins to treat dystrophinopathies
JP2023545546A (ja) 遺伝子発現調節のための非アニオン性ポリヌクレオチド類似体のペプチドに基づく導入
RU2021105152A (ru) Проникающие в клетку пептиды
CN100356981C (zh) 与人表皮生长因子受体egfr特异性结合的配体寡肽
CN107216371B (zh) 一种成人t细胞白血病的特异性靶向多肽及其应用
RU2023123089A (ru) Проникающие в клетки пептидные конъюгаты
KR101531944B1 (ko) Vegf에 특이적으로 결합하는 vegf-bpb
CN103421093A (zh) 介导zmiz1靶向敲除的转录激活子样效应因子核酸酶及其制法和应用
RU2004103078A (ru) Молекулы иммунного связывания, ингибирующие синцитиальное слияние клеток трофобласта